| scholarly article | Q13442814 |
| P50 | author | Douglas P. Kiel | Q46935730 |
| Nathalie Franchimont | Q47015108 | ||
| Angela M. Cheung | Q48657503 | ||
| Elizabeth J Samelson | Q57306616 | ||
| P2093 | author name string | Claus Christiansen | |
| Andrea Wang | |||
| Paul D Miller | |||
| Ogo Egbuna | |||
| Mary S Anthony | |||
| Nadia S Daizadeh | |||
| Nathalie Franchimont | |||
| Luanda Grazette | |||
| Suresh R Siddhanti | |||
| P2860 | cites work | Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation | Q24311588 |
| Osteoprotegerin: a novel secreted protein involved in the regulation of bone density | Q24313918 | ||
| osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification | Q24603266 | ||
| Denosumab for prevention of fractures in postmenopausal women with osteoporosis | Q28254528 | ||
| Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization | Q28283679 | ||
| Coronary calcification in patients with chronic kidney disease and coronary artery disease | Q33560509 | ||
| Comparison of estimated creatinine clearance among five formulae (Cockroft-Gault, Jelliffe, Sanaka, simplified 4-variable MDRD and DAF) and the 24hours-urine-collection creatinine clearance | Q33951218 | ||
| RANK ligand and osteoprotegerin: paracrine regulators of bone metabolism and vascular function | Q34123475 | ||
| A radiographic study on the associations of age and prevalence of vertebral fractures with abdominal aortic calcification in Japanese postmenopausal women and men | Q34211384 | ||
| Evaluating the performance of equations for estimating glomerular filtration rate. | Q35564754 | ||
| Osteoprotegerin/RANKL axis and progression of coronary artery calcification in hemodialysis patients | Q35995048 | ||
| Osteoprotegerin and RANKL regulate bone resorption, density, geometry and strength | Q36269835 | ||
| Osteoprotegerin reverses osteoporosis by inhibiting endosteal osteoclasts and prevents vascular calcification by blocking a process resembling osteoclastogenesis | Q36368706 | ||
| Vascular calcifications: pathogenesis, management, and impact on clinical outcomes. | Q36665930 | ||
| Vascular calcification and osteoporosis--from clinical observation towards molecular understanding | Q36676122 | ||
| The osteoprotegerin/RANK/RANKL system: a bone key to vascular disease | Q36686037 | ||
| Chronic kidney disease: effects on the cardiovascular system | Q36868237 | ||
| Osteoprotegerin inhibits vascular calcification without affecting atherosclerosis in ldlr(-/-) mice. | Q37188485 | ||
| Inhibition of receptor activator of NF-kappaB ligand by denosumab attenuates vascular calcium deposition in mice | Q37278407 | ||
| Association of coronary artery and aortic calcium with lumbar bone density: the MESA Abdominal Aortic Calcium Study | Q37306185 | ||
| Comparison of risk prediction using the CKD-EPI equation and the MDRD study equation for estimated glomerular filtration rate | Q37334515 | ||
| Radiographic measure of aorta calcification is a site-specific predictor of bone loss and fracture risk at the hip. | Q40324778 | ||
| Abdominal aortic calcific deposits are an important predictor of vascular morbidity and mortality | Q43546639 | ||
| Design and methods of the Raloxifene Use for The Heart (RUTH) study | Q43730182 | ||
| Osteoprotegerin inhibits artery calcification induced by warfarin and by vitamin D. | Q43764592 | ||
| Osteoprotegerin is a risk factor for progressive atherosclerosis and cardiovascular disease | Q43865169 | ||
| Increased plasma concentrations of osteoprotegerin in type 2 diabetic patients with microvascular complications | Q44490286 | ||
| Effective doses of ibandronate do not influence the 3-year progression of aortic calcification in elderly osteoporotic women | Q44936850 | ||
| Predictive performance of the modification of diet in renal disease and Cockcroft-Gault equations for estimating renal function. | Q45230608 | ||
| Associations of serum osteoprotegerin levels with diabetes, stroke, bone density, fractures, and mortality in elderly women | Q46130374 | ||
| RANKL inhibition with osteoprotegerin increases bone strength by improving cortical and trabecular bone architecture in ovariectomized rats | Q46212098 | ||
| Year-by-year analysis of cardiovascular events in the Multiple Outcomes of Raloxifene Evaluation (MORE) trial | Q46479671 | ||
| Aortic calcification and the risk of osteoporosis and fractures | Q46548686 | ||
| Volumetric BMD and Vascular Calcification in Middle-Aged Women: The Study of Women's Health Across the Nation | Q57392301 | ||
| Effects of denosumab on fracture and bone mineral density by level of kidney function | Q58970644 | ||
| Low serum levels of soluble RANK ligand are associated with the presence of coronary artery disease in men | Q73167301 | ||
| New indices to classify location, severity and progression of calcific lesions in the abdominal aorta: a 25-year follow-up study | Q73556145 | ||
| Progression of aortic calcification is associated with metacarpal bone loss during menopause: a population-based longitudinal study | Q74152546 | ||
| Serum osteoprotegerin levels are associated with the presence and severity of coronary artery disease | Q74711101 | ||
| Bone loss and the progression of abdominal aortic calcification over a 25 year period: the Framingham Heart Study | Q77084584 | ||
| Osteoprotegerin inactivation accelerates advanced atherosclerotic lesion progression and calcification in older ApoE-/- mice | Q79903873 | ||
| Progression of vascular calcifications is associated with greater bone loss and increased bone fractures | Q80461984 | ||
| Soluble receptor activator of nuclear factor-kappa B ligand and risk for cardiovascular disease | Q80589399 | ||
| French women, fractures and aortic calcifications | Q81162339 | ||
| Calcifications in the abdominal aorta predict fractures in men: MINOS study | Q81345932 | ||
| Serum levels of osteoprotegerin and RANKL in patients with ST elevation acute myocardial infarction | Q81801138 | ||
| P433 | issue | 2 | |
| P921 | main subject | aorta | Q101004 |
| osteoporosis | Q165328 | ||
| circulatory system | Q11068 | ||
| P304 | page(s) | 450-457 | |
| P577 | publication date | 2014-02-01 | |
| P1433 | published in | Journal of Bone and Mineral Research | Q15750941 |
| P1476 | title | RANKL inhibition with denosumab does not influence 3-year progression of aortic calcification or incidence of adverse cardiovascular events in postmenopausal women with osteoporosis and high cardiovascular risk | |
| P478 | volume | 29 |
| Q51776576 | Association of Circulating Wnt Antagonists With Severe Abdominal Aortic Calcification in Elderly Women. |
| Q44657342 | Bisphosphonates, atherosclerosis and vascular calcification: update and systematic review of clinical studies |
| Q33833414 | Chronic kidney disease and osteoporosis: evaluation and management |
| Q58715301 | Circulating osteogenic proteins are associated with coronary artery calcification and increase after myocardial infarction |
| Q60912319 | Common mechanisms and holistic care in atherosclerosis and osteoporosis |
| Q39296189 | Comparative Safety and Effectiveness of Denosumab Versus Zoledronic Acid in Patients With Osteoporosis: A Cohort Study |
| Q40765493 | Cortical bone laminar analysis reveals increased midcortical and periosteal porosity in type 2 diabetic postmenopausal women with history of fragility fractures compared to fracture-free diabetics. |
| Q56565085 | Denosumab for the treatment of osteoporosis. |
| Q38220743 | Denosumab: a review of its use in postmenopausal women with osteoporosis |
| Q61455229 | Effect of Resistance Exercise on Serum Osteoprotegerin Levels and Insulin Resistance in Middle-Aged Women with Metabolic Syndrome |
| Q35589102 | Effects of denosumab on bone density, mass and strength in women with postmenopausal osteoporosis |
| Q35070613 | Insights into aortic sclerosis and its relationship with coronary artery disease |
| Q38918810 | Intravenous Zoledronic Acid 5 mg on Bone Turnover Markers and Bone Mineral Density in East China Subjects with Newly Diagnosed Osteoporosis: A 24-month Clinical Study. |
| Q37292841 | Lower leg arterial calcification assessed by high-resolution peripheral quantitative computed tomography is associated with bone microstructure abnormalities in women |
| Q35852252 | Management of severe osteoporosis |
| Q28087423 | Molecular Mechanisms of Vascular Calcification in Chronic Kidney Disease: The Link between Bone and the Vasculature |
| Q38513410 | Osteoporosis and cardiovascular disease: an update |
| Q39255870 | Osteoporosis, bone mineral density and CKD-MBD: treatment considerations. |
| Q38703771 | Targeting local vascular and systemic consequences of inflammation on vascular and cardiac valve calcification |
| Q35260850 | Update on denosumab treatment in postmenopausal women with osteoporosis |
| Q38754124 | Vascular calcification in type-2 diabetes and cardiovascular disease: Integrative roles for OPG, RANKL and TRAIL. |
Search more.